A carregar...
The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease characterized by worsening dyspnea and lung function and has a median survival of 2–3 years. Forced vital capacity (FVC) is the primary endpoint used most commonly in IPF clinical trials as it is the best...
Na minha lista:
| Publicado no: | Ther Adv Respir Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8013716/ https://ncbi.nlm.nih.gov/pubmed/33781141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17534666211004238 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|